Primary Insomnia

🔍 Three Things You Likely Didn’t Know About Insomnia

1. Much of what we know about insomnia came from studying its opposite — narcolepsy. Narcolepsy is caused by the destruction of neurons that produce orexin, the brain’s master wakefulness signal — without it, patients collapse into sleep unpredictably. This discovery flipped the question: if too little orexin causes sleepiness, could blocking its excess help people sleep? The answer turns out is yes. In chronic insomnia, the orexin system remains abnormally active. This insight led to a new class of sleep medications — dual orexin receptor antagonists (DORAs) — with characteristics that make them much more attractive than traditional sedatives (Muehlan et al., 2023).

2. Sometimes insomnia means your treatment is working — not failing. As depression lifts, energy returns before emotional equilibrium does — and a person who spent months numbed may now have the bandwidth to confront grief or trauma they had been unable to process. REM sleep functions as “overnight therapy,” actively reprocessing emotionally charged memories (Walker & van der Helm, 2009) — and when it encounters a backlog, sleep fragments temporarily. Recognizing this pattern prevents premature medication changes and opens the door to targeted interventions that support the healing already underway.

3. Many patients are never told the real risks of long-term sleeping pills — including possible structural brain changes. Prolonged use of certain sleep medications has been linked to cognitive impairment, increased fall risk, rebound insomnia, and in some studies, elevated mortality risk (Kripke, 2016). Large population studies have also found that long-term benzodiazepine users show smaller hippocampal, amygdala, and thalamic volumes with accelerated brain volume loss over time — though whether this reflects a direct drug effect or confounding by the conditions being treated remains debated (Vom Hofe et al., 2024). These findings mean that sleep medications can be helpful, but should be used thoughtfully and only as needed while other safer interventions start to provide benefit.

---

📋 Overview

Primary insomnia — now formally termed insomnia disorder in the DSM-5 — is defined as persistent difficulty initiating sleep, maintaining sleep, or experiencing nonrestorative sleep that occurs at least three nights per week for at least three months and causes clinically significant distress or functional impairment. Crucially, the diagnosis applies when insomnia has taken on an independent clinical trajectory — even if another condition initially triggered it.

Chronic insomnia affects approximately 10% of adults. Its consequences extend far beyond nighttime frustration — sleep deprivation impairs attention, memory consolidation, emotional regulation, immune function, and metabolic health. Insomnia is an independent risk factor for depression, anxiety disorders, substance use disorders, cardiovascular disease, and chronic pain syndromes.

The pathophysiology of chronic insomnia is best understood through Spielman’s 3P model — predisposing factors (genetic vulnerability, temperamental traits such as perfectionism or worry-proneness), precipitating factors (a stressful event, medical illness, or schedule disruption that initially triggers sleep difficulty), and perpetuating factors (maladaptive behaviors and cognitive patterns that maintain the insomnia long after the original trigger has resolved). In most cases, the perpetuating factors are what keep the condition alive — and they are highly modifiable.

At the neurobiological level, chronic insomnia involves a failure to downregulate arousal at the sleep-wake transition — the brain’s waking networks fail to fully “deactivate” at sleep onset, resulting in a hybrid state of partial arousal. The circuits governing this switch — including the orexin system — have become targets for a new class of sleep medications.

---

🔀 Subtypes and Presentations

While insomnia disorder is a unified diagnosis, its clinical presentation varies considerably:

• Sleep-onset insomnia — difficulty falling asleep at the beginning of the night. This is the most common presentation in younger adults and is strongly associated with cognitive hyperarousal (racing thoughts, worry, anticipatory anxiety about sleep itself).
• Sleep-maintenance insomnia — difficulty staying asleep, with frequent or prolonged nighttime awakenings. More common in middle-aged and older adults and may reflect circadian or hormonal influences.
• Early-morning awakening insomnia — waking well before the desired time feeling “wide awake” and being unable to return to sleep. This presentation has a particularly strong association with mood disorders, especially depression.
• Mixed presentation — many patients experience elements of all three patterns, and the dominant pattern may shift over time.
• Paradoxical insomnia (sleep-state misperception) — a subtype in which patients report severe insomnia but objective sleep measurements (polysomnography) show relatively normal total sleep time. This does not mean the patient is imagining the problem — it reflects a genuine alteration in how the brain perceives its own sleep, and these patients often have the same hyperarousal markers as those with objectively shortened sleep.

---

🩺 Diagnosis

Accurate diagnosis of insomnia disorder requires more than documenting poor sleep. A thorough evaluation should include:

• Detailed sleep history — timing of sleep and wake, time in bed, estimated sleep latency and wake-after-sleep-onset, variability across nights, weekend versus weekday patterns, and duration of the complaint. Sleep diaries completed over one to two weeks can assist with challenging situations.
• Assessment of daytime consequences — fatigue, cognitive difficulties, mood disturbance, and functional impairment at work or in relationships.
• Screening for comorbid conditions — depression, anxiety, PTSD, substance use, chronic pain, restless legs syndrome, and obstructive sleep apnea can all worsen insomnia.
• Medication and substance review — caffeine, alcohol, stimulants, certain antidepressants, corticosteroids, and many other substances can profoundly disrupt sleep.
• Ruling out other primary sleep disorders — when history suggests possible sleep apnea, periodic limb movements, or another intrinsic sleep disorder, polysomnography or home sleep testing may be warranted.
• Behavioral assessment — identifying perpetuating behaviors such as excessive time in bed, irregular sleep schedules, napping patterns, and use of screens or stimulating activities near bedtime.

Standardized instruments such as the Insomnia Severity Index (ISI) can provide useful quantitative measures during intake or for tracking treatment response.

---

💊 Treatment Approach

Psychotherapy

Cognitive-behavioral therapy for insomnia (CBT-I) is typically the first-line treatment for chronic insomnia. For patients whose insomnia is driven by ruminative worry or metacognitive processes (e.g., “worrying about not sleeping”), mindfulness-based therapy for insomnia (MBTI) and acceptance and commitment therapy (ACT) offer complementary approaches that can help reduce the hyperarousal that fuels the cycle.

Medication and Neuromodulation

When medication is warranted — whether as a bridge during the early weeks of CBT-I, for short-term relief during acute crises, or for patients who have not responded adequately to behavioral treatment alone — several pharmacological classes are available, each working through distinct neurochemical mechanisms:

• Orexin receptor antagonists — rather than broadly sedating the brain, these agents selectively block the wake-promoting orexin system, allowing sleep to emerge more naturally. The safety profile of this class is notably favorable — independent meta-analyses have found no evidence of physical dependence, tolerance, or rebound insomnia, making them a compelling option when longer-term pharmacotherapy is warranted (Khazaie et al., 2022).
• Melatonin receptor agonists beyond melatonin that target the circadian signaling system and may be particularly useful when the timing of sleep onset is part of the problem.
• GABA-modulating agents — including both benzodiazepine and non-benzodiazepine hypnotics — have been the traditional pharmacological approach. They can be effective for short-term use but carry risks of tolerance, dependence, and cognitive side effects with prolonged use.
• Certain sedating antidepressants and antihistamines are sometimes used off-label for insomnia and can be highly helpful subjectively in specific patients.

The choice among these options depends on the patient’s clinical profile, comorbidities, prior medication history, and goals — weighing not just efficacy but long-term safety, dependency risk, and the trajectory toward sustainable sleep.

Neuromodulation approaches for insomnia remain an active area of investigation. Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) targeting arousal-regulating circuits have shown promising preliminary results and may become clinically relevant tools in the near future.

Integrative and Lifestyle Approaches

Sleep is one of the domains where integrative approaches have a compelling evidence base. Specific interventions targeting baseline anxiety levels, hyper-arousal states, the circadian system, the stress-neuroendocrine axis, the gut-brain connection, and inflammatory pathways can meaningfully complement conventional treatment when selected with precision. These are targeted strategies informed by sleep neuroscience.

---

🌱 Outlook

Chronic insomnia is one of the most treatable conditions in psychiatry and sleep medicine. Combined treatment of appropriate psychotherapy and short-term, low-dose medication — followed by medication taper — produces remission in up to 68% of patients, with durable gains that persist months to years after treatment ends (Morin & Buysse, 2024).

The goal of treatment is not merely to increase total sleep time — it is to restore confidence in one’s ability to sleep, eliminate the dread and hypervigilance that surround bedtime, and reclaim the daytime alertness and emotional resilience that healthy sleep provides.

Insomnia does not have to be a lifelong condition. While predisposing factors (such as a tendency toward hyperarousal) may persist, the perpetuating factors that keep insomnia alive are modifiable and reversible. With the right approach, the brain can both sleep and relearn how to sleep naturally.

---

🏥 How to Get Better

At our psychiatry practice, we treat primary insomnia with an evidence-based, multimodal approach — combining specialized psychotherapy for sleep with precision medication when appropriate, and integrating neuromodulation, targeted supplements, stress management, and lifestyle strategies for patients who want a broader toolkit.

Ready to get started? Schedule an intake appointment — a thorough evaluation where we clarify your diagnosis, map out your treatment plan, and get everything moving: medication orders, therapy, supplements, and nutrition. Your care begins the same day, not weeks later.

Schedule Your Intake

We offer statewide telehealth services in California and Florida, with in-person appointments available in Los Angeles and Miami. We also regularly assist international patients due to our fluency in Portuguese, Spanish, and Farsi.

---

📚 References

1. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). American Psychiatric Publishing.
2. Morin, C. M., & Benca, R. M. (2012). Chronic insomnia. The Lancet, 379(9821), 1129-1141.
3. Mitchell, M. D., Gehrman, P., Perlis, M., & Umscheid, C. A. (2012). Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Family Practice, 13, 40.
4. Qaseem, A., Kansagara, D., Forciea, M. A., et al. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.
5. Spielman, A. J., Caruso, L. S., & Glovinsky, P. B. (1987). A behavioral perspective on insomnia treatment. Psychiatric Clinics of North America, 10(4), 541-553.
6. Bonnet, M. H., & Arand, D. L. (2010). Hyperarousal and insomnia: state of the science. Sleep Medicine Reviews, 14(1), 9-15.
7. Bootzin, R. R., & Epstein, D. R. (2011). Understanding and treating insomnia. Annual Review of Clinical Psychology, 7, 435-458.
8. Trauer, J. M., Qian, M. Y., Doyle, J. S., Rajaratnam, S. M., & Cunnington, D. (2015). Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Annals of Internal Medicine, 163(3), 191-204.
9. Kripke, D. F. (2016). Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Research, 5, 918.
10. Morin, C. M., & Buysse, D. J. (2024). Management of insomnia. New England Journal of Medicine, 391(3), 247-258.
11. Walker, M. P., & van der Helm, E. (2009). Overnight therapy? The role of sleep in emotional brain processing. Psychological Bulletin, 135(5), 731-748.
12. Samson, D. R., Crittenden, A. N., Mabulla, I. A., Mabulla, A. Z., & Nunn, C. L. (2017). Chronotype variation drives night-time sentinel-like behaviour in hunter-gatherers. Proceedings of the Royal Society B, 284(1858), 20170967.
13. Riemann, D., Baglioni, C., Bassetti, C., et al. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.
14. Vom Hofe, I., et al. (2024). Benzodiazepine use in relation to long-term dementia risk and imaging markers of neurodegeneration and vascular pathology. BMC Medicine, 22(1), 266.
15. Khazaie, H., et al. (2022). Dual orexin receptor antagonists for treatment of insomnia: a systematic review and meta-analysis on clinical outcomes. Frontiers in Psychiatry, 13, 1070522.
16. Muehlan, C., Roch, C., Vaillant, C., & Dingemanse, J. (2023). The orexin story and orexin receptor antagonists for the treatment of insomnia. Journal of Sleep Research, 32(6), e13902.